MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318353 | Name: Nebivolol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nebivolol is a β1 receptor blocker with nitric oxide-potentiating vasodilatory effect used in treatment of hypertension and, in Europe, also for left ventricular failure. It is highly cardioselective under certain circumstances.

Chemical Structure

Nebivolol
Nebivolol
CAS#118457-14-0

Theoretical Analysis

MedKoo Cat#: 318353

Name: Nebivolol

CAS#: 118457-14-0

Chemical Formula: C22H25F2NO4

Exact Mass: 405.1752

Molecular Weight: 405.44

Elemental Analysis: C, 65.17; H, 6.22; F, 9.37; N, 3.45; O, 15.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
R 065824; R065824; R-065824; Nebivolol; Nobiten; Vasoxen
IUPAC/Chemical Name
1-((R)-6-fluorochroman-2-yl)-2-(((R)-2-((R)-6-fluorochroman-2-yl)-2-hydroxyethyl)amino)ethanol
InChi Key
KOHIRBRYDXPAMZ-JJTQDJFQSA-N
InChi Code
InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2/t17-,18?,21-,22-/m1/s1
SMILES Code
O[C@H](CNCC([C@H]1CCC2=CC(F)=CC=C2O1)O)[C@H]3CCC4=CC(F)=CC=C4O3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 405.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sander GE, Giles TD. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension. Expert Opin Pharmacother. 2015 Apr;16(5):763-70. doi: 10.1517/14656566.2015.1020790. Review. PubMed PMID: 25747524. 2: Howlett JG. Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease. Can J Cardiol. 2014 May;30(5 Suppl):S29-37. doi: 10.1016/j.cjca.2014.03.003. Epub 2014 Mar 5. Review. PubMed PMID: 24750980. 3: Varagic J, Punzi H, Ferrario CM. Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. Integr Blood Press Control. 2014 Nov 26;7:61-70. doi: 10.2147/IBPC.S50954. eCollection 2014. Review. PubMed PMID: 25473311; PubMed Central PMCID: PMC4251532. 4: Patrascu N. Diastolic heart failure in hypertension: possible preventive benefits of nebivolol beyond lowering blood pressure. Maedica (Buchar). 2013 Sep;8(3):285-9. Review. PubMed PMID: 24371501; PubMed Central PMCID: PMC3869121. 5: DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol. 2013 Mar 1;111(5):765-9. doi: 10.1016/j.amjcard.2012.11.031. Epub 2013 Jan 4. Review. PubMed PMID: 23290925. 6: Toblli JE, DiGennaro F, Giani JF, Dominici FP. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag. 2012;8:151-60. doi: 10.2147/VHRM.S20669. Epub 2012 Mar 13. Review. PubMed PMID: 22454559; PubMed Central PMCID: PMC3310359. 7: Gao Y, Vanhoutte PM. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker. J Cardiovasc Pharmacol. 2012 Jan;59(1):16-21. doi: 10.1097/FJC.0b013e3182073e27. Review. PubMed PMID: 21283024. 8: Riva N, Lip GY. Nebivolol for the treatment of heart failure. Expert Opin Investig Drugs. 2011 Dec;20(12):1733-46. doi: 10.1517/13543784.2011.625011. Epub 2011 Oct 8. Review. PubMed PMID: 21980961. 9: Del Sindaco D, Tinti MD, Monzo L, Pulignano G. Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure. Clin Interv Aging. 2010 Dec 3;5:381-93. doi: 10.2147/CIA.S4482. Review. PubMed PMID: 21152240; PubMed Central PMCID: PMC2998246. 10: Giles TD. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol. Am J Med. 2010 Jul;123(7 Suppl 1):S16-20. doi: 10.1016/j.amjmed.2010.04.014. Review. PubMed PMID: 20609694. 11: Bakris GL, Basile JN, Giles TD, Taylor AA. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Am J Med. 2010 Jul;123(7 Suppl 1):S2-8. doi: 10.1016/j.amjmed.2010.04.012. Review. PubMed PMID: 20609695. 12: Gauthier C, Trochu JN. [Nebivolol: the first vasodilatory beta-blocker with a beta3-adrenergic agonist activity]. Ann Cardiol Angeiol (Paris). 2010 Jun;59(3):155-9. doi: 10.1016/j.ancard.2010.05.003. Review. French. PubMed PMID: 20620250. 13: Lipsic E, van Veldhuisen DJ. Nebivolol in chronic heart failure: current evidence and future perspectives. Expert Opin Pharmacother. 2010 Apr;11(6):983-92. doi: 10.1517/14656561003694650. Review. PubMed PMID: 20307222. 14: Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9. doi: 10.1016/j.jacc.2009.05.066. Review. PubMed PMID: 19815121. 15: Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):329-34. doi: 10.1177/1753944709339968. Review. PubMed PMID: 19638367. 16: Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol. 2009 Aug;54(2):123-8. doi: 10.1097/FJC.0b013e3181ad207b. Review. PubMed PMID: 19528811. 17: Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27. doi: 10.1177/1753944709104496. Epub 2009 May 14. Review. PubMed PMID: 19443516. 18: Baldwin CM, Keam SJ. Nebivolol: in the treatment of hypertension in the US. Am J Cardiovasc Drugs. 2009;9(4):253-60. doi: 10.2165/1120274-000000000-00000. Review. PubMed PMID: 19655820. 19: Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5(1):353-60. Review. PubMed PMID: 19475771; PubMed Central PMCID: PMC2686253. 20: O'Malley P. Nebivolol: a new third-generation beta-blocker agent: implications for Clinical Nurse Specialist Practice. Clin Nurse Spec. 2008 May-Jun;22(3):126-8. doi: 10.1097/01.NUR.0000311691.85038.02. Review. PubMed PMID: 18438160.

View History

Urefibrate

Urefibrate